文献速递药物不良反应与药物警戒治疗药物监测与药物基因组学

以药物基因组学革新药物警戒:迈向个体化风险管理

Transforming Pharmacovigilance With Pharmacogenomics: Toward Personalized Risk Management.
PubMed 文献 · Clin Pharmacol Ther · 2025-10-27

药物警戒是用药安全的关键环节,但部分不良反应仅在药物广泛长期使用后才会被发现。本文概述当前药物警戒与药物基因组学实践,指出将药物基因组学纳入药物警戒项目可解释部分个体化不良反应,并推荐将其作为调查中的关键数据点。

要点

  • 药物基因组学标记可解释部分个体化不良反应。
  • 将药物基因组学指导纳入处方可减少不良反应并改善临床结局。
  • 推荐药物警戒项目将药物基因组学作为关键数据点。

核心结论

  • 药物警戒项目应将药物基因组学作为调查中的关键数据点。

主要发现

  • 药物基因组学标记可帮助解释部分个体化不良反应。
  • 将药物基因组学指导纳入处方已被证明可减少不良反应发生率并改善临床结局。
  • 药物基因组学信息尚未常规纳入事件报告。

临床怎么用

  • 处方时可结合药物基因组学检测结果进行个体化用药。
  • 药物警戒项目调查中应纳入药物基因组学数据。

局限性

  • 药物基因组学信息尚未常规纳入事件报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pharmacovigilance is a critical component of medication safety. Despite rigorous evaluation of new drugs during clinical trials, some adverse effects might only be identified once pharmaceuticals are used by a larger population for a longer duration. Adverse drug reactions cause negative healthcare outcomes and in severe cases, may lead to hospital admissions, delayed hospital discharges, or deaths. Adverse event reports submitted to pharmacovigilance programs by healthcare professionals and consumers are a key source of information regarding previously unrecognized detrimental effects. Pharmacogenetic markers that indicate how particular genes impact an individual's response to medication can help explain some idiosyncratic adverse reactions. Incorporating pharmacogenomic guidance in prescribing is proven to decrease the incidence of adverse reactions and improve clinical outcomes. However, this information is not yet routinely included in incident reports. In this era of precision medicine, when prescribing can be tailored to the individual, pharmacogenomic test results yield valuable data that can enhance both individual and population health. Furthermore, advanced artificial intelligence (AI) and machine learning (ML) methods facilitate analysis of complex genetic data, revealing insights not previously available. This white paper outlines current pharmacovigilance and pharmacogenomic practices and recommends that pharmacovigilance programs include pharmacogenomics as a crucial data point in their investigations.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Spahn C, Toda N, Groat B, et al. Transforming Pharmacovigilance With Pharmacogenomics: Toward Personalized Risk Management. Clin Pharmacol Ther. 2025. PMID: 41146533. doi:10.1002/cpt.70095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。